2018
Long-Term Survivors of Pancreatic Cancer
Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer. Pancreas 2018, 47: 958-966. PMID: 30074526, PMCID: PMC6095724, DOI: 10.1097/mpa.0000000000001133.Peer-Reviewed Original ResearchConceptsLong-term survivalPancreatic cancerPancreatic adenocarcinomaCalifornia Cancer RegistryLong-term survivorsPancreatic cancer mortalityAsian/Pacific IslandersNational Cancer InstituteNon-Hispanic whitesAdjuvant chemotherapyUnresectable patientsBaseline characteristicsSurgical resectionTerm survivorsCancer RegistryPoor prognosisSurgical interventionCancer CenterCancer mortalityDegree of differentiationCancer InstituteSurvival rateYounger ageLogistic regressionPatients
2015
Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.
Alagappan M, Pollom E, von Eyben R, Kunz P, Fisher G, Ford J, Poultsides G, Visser B, Norton J, Kamaya A, Columbo L, Koong A, Chang D. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. Journal Of Clinical Oncology 2015, 33: 433-433. DOI: 10.1200/jco.2015.33.3_suppl.433.Peer-Reviewed Original ResearchUnresectable pancreatic adenocarcinomaStereotactic body radiotherapyHigh NL ratioPrior radiation therapyOverall survivalBlood cell countStart of treatmentPancreatic adenocarcinomaTumor marker valuesNL ratioResectable diseaseEntire cohortCA 19Univariate analysisRadiation therapyCell countWhite blood cell countTumor marker CA 19Marker valuesLab valuesBorderline resectable diseasePre-treatment CEAMedian overall survivalAbsolute lymphocyte countAbsolute neutrophil count
2014
Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT. Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: 918-925. PMID: 25585785, DOI: 10.1016/j.ijrobp.2014.06.066.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyCumulative incidence rateSingle-fraction groupUnresectable pancreatic adenocarcinomaBody radiation therapyPancreatic adenocarcinomaToxicity gradeSurvival rateLocal recurrenceIncidence rateRadiation therapySingle-fraction stereotactic body radiation therapyGastrointestinal toxicity gradeMajority of patientsGastrointestinal toxicityMedian survivalWorse survivalIndependent predictorsPancreatic cancerLocal controlPatientsAdenocarcinomaRecurrenceTherapyMonthsPostradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma
Shultz DB, Chan C, Shaffer JL, Kunz PL, Koong AC, Chang DT. Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Pancreas 2014, 43: 777-783. PMID: 24632549, DOI: 10.1097/mpa.0000000000000098.Peer-Reviewed Original ResearchConceptsPostoperative chemoradiotherapyPancreatic ductal adenocarcinomaDuctal adenocarcinomaNonmetastatic pancreatic ductal adenocarcinomaCA19-9 kineticsPretreatment CA19-9Carbohydrate antigen 19Definitive chemoradiotherapyRadiotherapy correlatesOverall survivalMultivariable analysisAntigen 19CA19-9Disease progressionPancreatic adenocarcinomaTreatment decisionsChemoradiotherapyPrognostic toolPatientsKinetics correlateAdenocarcinomaRT correlateFFPTTNProgressionOutcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.
Pollom E, Alagappan M, Chan C, Shultz D, Kunz P, Koong A, Chang D. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 317-317. DOI: 10.1200/jco.2014.32.3_suppl.317.Peer-Reviewed Original ResearchStereotactic body radiotherapyUnresectable pancreatic adenocarcinomaGy x 5Pancreatic adenocarcinomaPrior RTCurrent chemoResectable diseaseTumor locationTime of SBRTToxicity of SBRTLocal controlBorderline resectable diseaseGood local controlUse of chemotherapyDate of diagnosisCommon treatment regimensBetter OSMedian OSOS ratesAdvanced diseaseGI toxicityCumulative incidenceLocal recurrenceBody radiotherapyTreatment regimens
2013
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness
Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. Hepato Pancreato Biliary 2013, 16: 304-311. PMID: 23991643, PMCID: PMC3967881, DOI: 10.1111/hpb.12139.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCell DifferentiationChi-Square DistributionFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeuroendocrine TumorsPancreatectomyPancreatic NeoplasmsPredictive Value of TestsProportional Hazards ModelsRetrospective StudiesRisk FactorsTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsPancreatic neuroendocrine tumorsOverall survivalArterial phasePre-operative decisionsSynchronous liver metastasesWorse overall survivalMultidisciplinary treatmentSurgical resectionIndependent predictorsLiver metastasesLymph nodesPoor outcomePrognostic significanceClinicopathological variablesNeuroendocrine tumorsCT appearancePancreatic adenocarcinomaBiological aggressivenessTumor enhancementMultivariate analysisTumorsHypoenhancementIntermediate gradeResectionPatients
2012
Penile metastases originating from a pancreatic primary tumor: a case report
Tello T, Zeidan Y, Bush K, Schwartz E, Kunz P, Chang D. Penile metastases originating from a pancreatic primary tumor: a case report. Journal Of Radiation Oncology 2012, 2: 107-112. DOI: 10.1007/s13566-012-0076-1.Peer-Reviewed Original ResearchPenile metastasisPancreatic adenocarcinomaPrimary tumorPancreatic primary tumorExternal beam radiationPrimary pancreatic adenocarcinomaFine needle aspiratesPalliative radiationPenile painPain controlDifficulty urinatingPancreatic bodyInfiltrative massMetastatic adenocarcinomaCase reportPancreatic massPenile diseaseRadiation therapyComputed tomographyGenitourinary systemPenile nodulesNeedle aspiratesAdenocarcinomaMetastasisBeam radiation
2011
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e595-e601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival RateConceptsIntensity-modulated radiotherapyLocal-regional control ratesPancreatic adenocarcinomaAdjuvant patientsDefinitive patientsControl rateSurvival rateGrade 3 late toxicityRecurrence-free survival ratesThree-dimensional conformal radiotherapyOverall survival rateProspective clinical trialsRecurrence-free survivalDurable disease controlPlanning target volumeGreater acute toxicityAcute toxicityLate toxicityOverall survivalSystemic therapyMedian agePancreatic cancerClinical trialsPrescription doseGrade 3Long-term survivorship in pancreatic adenocarcinoma.
Gubens M, Kunz P, Fisher G, Ford J, Lichtensztajn D, Clarke C. Long-term survivorship in pancreatic adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 175-175. DOI: 10.1200/jco.2011.29.4_suppl.175.Peer-Reviewed Original ResearchLong-term survivalLong-term survivorsStage diseasePancreatic adenocarcinomaPancreatic cancerAcademic hospitalSocioeconomic statusHigher long-term survivalMultivariate logistic regression modelPrior cancer historyCalifornia Cancer RegistryMonths of diagnosisRegional-stage diseasePopulation-based registryCase-control studyAsian/Pacific IslandersNon-Hispanic blacksUse of tumorLong-term survivorshipNon-Hispanic whitesLogistic regression modelsHigher socioeconomic statusRace/ethnicityMedian survivalMetastatic disease
2010
Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma
Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer 2010, 116: 5179-5187. PMID: 20665497, DOI: 10.1002/cncr.25481.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCarbonic Anhydrase IXCarbonic AnhydrasesCell HypoxiaCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleHumansImmunohistochemistryMaleMiddle AgedPancreatic NeoplasmsPoly(ADP-ribose) PolymerasesPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTetrahydrofolate DehydrogenaseTissue Array AnalysisConceptsProgression-free survivalOverall survivalPoly adenosine diphosphate-ribose polymerasePancreatic adenocarcinomaImproved OSImmunohistochemical expressionHypoxia markersImproved overall survivalCyclin-dependent kinase inhibitor 2AExpression of p16INK4aCarbonic anhydrase IXAdjuvant chemotherapyCurative resectionMedian survivalImproved survivalMargin statusClinical outcomesPrimary tumorPancreatic cancerUnivariate analysisSurgical specimensImmunohistochemical stainingTissue microarrayPositive stainingPatients